Mintz served as legal counsel to clinical-stage biopharmaceutical company Neurotrope, Inc. (NASDAQ: NTRP) in its definitive merger agreement with Metuchen Pharmaceuticals, LLC, a privately held biopharmaceutical company focused on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health conditions. Per the agreement, the companies will merge in an all-stock transaction resulting in a newly formed holding company to be renamed Petros Pharmaceuticals, Inc. (Petros) focused solely on men's health conditions.

Upon completion of the proposed merger, expected to close during the third quarter of 2020, Petros' cornerstone product would be Metuchen Pharmaceutical’s drug for erectile dysfunction, and its pipeline would include a product for Peyronie's disease, in addition to other business development programs for men’s health products.

In connection with the merger, Neurotrope intends to spin-off its wholly-owned subsidiary, Neurotrope Bioscience, Inc. (NBI), into a new separately traded entity focused on expanding NBI’s work to develop novel therapies for neurodegenerative diseases and developmental disorders. The company has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. In addition to continuing work on Alzheimer's disease, NBI plans to continue pursuing other indications using bryostatin such as Multiple Sclerosis and Fragile X syndrome.

The Mintz team advising Neurotrope is led by Members Kenneth Koch and Daniel Bagliebter, and included Members Jeffrey Schultz and Avi Reshtick, and Associates David Conway, Nishant Dharia, Stephanie Leopold, David Salamon, and Zane Polston.